GT200300179A - Profarmaco inhibidor de beta-lactamasa - Google Patents

Profarmaco inhibidor de beta-lactamasa

Info

Publication number
GT200300179A
GT200300179A GT200300179A GT200300179A GT200300179A GT 200300179 A GT200300179 A GT 200300179A GT 200300179 A GT200300179 A GT 200300179A GT 200300179 A GT200300179 A GT 200300179A GT 200300179 A GT200300179 A GT 200300179A
Authority
GT
Guatemala
Prior art keywords
profarmaco
lactamasa
beta
inhibitor
profarmacy
Prior art date
Application number
GT200300179A
Other languages
English (en)
Inventor
Anthony Marfat
Dale Gordon Mcleod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200300179A publication Critical patent/GT200300179A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D499/21—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a nitrogen atom directly attached in position 6 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D499/44—Compounds with an amino radical acylated by carboxylic acids, attached in position 6
    • C07D499/48—Compounds with an amino radical acylated by carboxylic acids, attached in position 6 with a carbon chain, substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, attached to the carboxamido radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A UN PROFARMACO EN LA QUE R ES UN GRUPO FUNCIONAL DESCRITO EN EL EXPEDIENTE Y CUYA ESTRUCTURA SE OBSERVA EN EL RESUMEN. ESTE PROFARMACO VA A AUMENTAR LA EFICACIA TERAPEUTICA DE UN ANTIBIOTICO BETALACTAMICO.
GT200300179A 2002-08-23 2003-08-22 Profarmaco inhibidor de beta-lactamasa GT200300179A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40564002P 2002-08-23 2002-08-23

Publications (1)

Publication Number Publication Date
GT200300179A true GT200300179A (es) 2004-05-18

Family

ID=31946909

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200300179A GT200300179A (es) 2002-08-23 2003-08-22 Profarmaco inhibidor de beta-lactamasa

Country Status (31)

Country Link
US (1) US7091197B2 (es)
EP (1) EP1534717B1 (es)
JP (1) JP2005539037A (es)
KR (1) KR20050037583A (es)
CN (1) CN1688589A (es)
AP (1) AP2005003231A0 (es)
AR (1) AR041028A1 (es)
AT (1) ATE349452T1 (es)
AU (1) AU2003250489A1 (es)
BR (1) BR0313683A (es)
CA (1) CA2494953A1 (es)
DE (1) DE60310733D1 (es)
EA (1) EA007540B1 (es)
EC (1) ECSP055625A (es)
GT (1) GT200300179A (es)
HR (1) HRP20050162A2 (es)
IL (1) IL166719A0 (es)
IS (1) IS7693A (es)
MA (1) MA27387A1 (es)
MX (1) MXPA05001446A (es)
NO (1) NO20051497L (es)
NZ (1) NZ538340A (es)
OA (1) OA12909A (es)
PA (1) PA8579701A1 (es)
PE (1) PE20040899A1 (es)
PL (1) PL375988A1 (es)
TN (1) TNSN05054A1 (es)
TW (1) TWI250162B (es)
UY (1) UY27947A1 (es)
WO (1) WO2004018484A1 (es)
ZA (1) ZA200501513B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0410936A (pt) * 2003-06-05 2006-06-27 Pfizer Prod Inc pró-fármaco inibidor da beta-lactamase
US20060105941A1 (en) * 2004-11-12 2006-05-18 Allergan, Inc. Mixed antibiotic codrugs
WO2007012319A1 (de) * 2005-07-29 2007-02-01 Sigma-Aldrich Production Gmbh Ionisierungsadditive enthaltende lc/ms-blends
WO2010118968A1 (en) 2009-04-16 2010-10-21 Nicox S.A. No-donor aspirin derivatives
WO2013056163A1 (en) * 2011-10-14 2013-04-18 The Regents Of The University Of California Beta-lactamase inhibitors
CA2860672A1 (en) * 2012-01-06 2013-07-11 University Of South Florida Compositions, methods of use, and methods of treatment
CN109422765B (zh) * 2017-09-05 2020-08-28 香港理工大学深圳研究院 C类β-内酰胺酶抑制剂及其制备方法和应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE34011B1 (en) 1969-03-13 1975-01-08 Leo Pharm Prod Ltd New penicillin esters
IE34019B1 (en) 1969-03-18 1975-01-08 Leo Pharm Prod Ltd New semi-synthetic penicillin esters
GB1267936A (en) 1969-05-28 1972-03-22 Beecham Group Ltd DERIVATIVES OF alpha-AMINOPENICILLINS
US3957764A (en) 1969-11-11 1976-05-18 Lovens Kemiske Fabrik Produktionsaktieselskab 6-aminopenicillanic acid derivatives
US3862181A (en) 1970-10-28 1975-01-21 Squibb & Sons Inc Process for preparing cephalosporins
GB1315566A (en) 1970-11-06 1973-05-02 Leo Pharm Prod Ltd Penicillanic acid derivatives
CA996929A (en) 1971-04-05 1976-09-14 Kohzi Nakano Acyloxyalkyl ester derivatives of penicillin
GB1433131A (en) 1972-03-13 1976-04-22 Astra Laekemedel Ab Penicillins
GB1426717A (en) 1972-03-13 1976-03-03 Astra Laekemedel Ab Penicillins
US4397783A (en) 1979-03-05 1983-08-09 Pfizer Inc. Process for converting 6,6-disubstituted penicillanic acid derivatives to the 6-β-congeners
DE2927004A1 (de) * 1979-07-04 1981-05-27 Bayer Ag, 5090 Leverkusen Penicillansaeure-1,1-dioxide, ihre herstellung und ihre verwendung als arzneimittel als arzneimittel
US4287181A (en) * 1979-10-22 1981-09-01 Pfizer Inc. Derivatives of 6β-hydroxyalkylpenicillanic acids as β-lactamase inhibitors
US4432970A (en) 1979-11-23 1984-02-21 Pfizer Inc. 6-beta-Halopenicillanic acid 1,1-dioxides as beta-lactamase inhibitors
GB2076812A (en) * 1980-05-22 1981-12-09 Ciba Geigy Ag Penam-dioxide compounds, processes for their manufacture, and their use
JPS5849387A (ja) 1981-09-17 1983-03-23 Sankyo Co Ltd ７−メトキシセフアロスポリン化合物およびその製法
AU559689B2 (en) * 1981-09-22 1987-03-19 Kureha Kagaku Kogyo K.K. Penicillin derivative
US4406887A (en) 1981-10-13 1983-09-27 Bristol-Myers Company Method for treating resistant bacteria including anaerobes
US4428935A (en) * 1982-05-24 1984-01-31 Pfizer Inc. Penicillanic acid dioxide prodrug
US4521533A (en) 1984-07-12 1985-06-04 Pfizer Inc. Salts of 6-alpha-(aminomethyl)penicillanic acid 1,1-dioxide esters and beta-lactam antibiotics
DE3901405A1 (de) 1989-01-19 1990-07-26 Hoechst Ag Cephalosporinderivate und verfahren zu ihrer herstellung
JPH03206038A (ja) 1990-01-08 1991-09-09 Yoshitomi Pharmaceut Ind Ltd 抗菌剤
GB9001405D0 (en) 1990-01-22 1990-03-21 Leo Pharm Prod Ltd New intermediates,their production and use
GB9208492D0 (en) 1992-04-16 1992-06-03 Glaxo Spa Heterocyclic compounds
BRPI0410936A (pt) 2003-06-05 2006-06-27 Pfizer Prod Inc pró-fármaco inibidor da beta-lactamase

Also Published As

Publication number Publication date
MA27387A1 (fr) 2005-06-01
TW200417548A (en) 2004-09-16
US7091197B2 (en) 2006-08-15
IS7693A (is) 2005-02-10
EA200500398A1 (ru) 2005-08-25
NO20051497D0 (no) 2005-03-21
EP1534717A1 (en) 2005-06-01
US20040110740A1 (en) 2004-06-10
HRP20050162A2 (en) 2005-06-30
WO2004018484A1 (en) 2004-03-04
AP2005003231A0 (en) 2005-03-31
KR20050037583A (ko) 2005-04-22
EP1534717B1 (en) 2006-12-27
ZA200501513B (en) 2006-09-27
JP2005539037A (ja) 2005-12-22
MXPA05001446A (es) 2005-06-06
CN1688589A (zh) 2005-10-26
ATE349452T1 (de) 2007-01-15
ECSP055625A (es) 2005-04-18
TNSN05054A1 (fr) 2007-05-14
NZ538340A (en) 2006-10-27
AU2003250489A1 (en) 2004-03-11
UY27947A1 (es) 2004-03-31
PE20040899A1 (es) 2004-12-28
CA2494953A1 (en) 2004-03-04
NO20051497L (no) 2005-03-21
DE60310733D1 (de) 2007-02-08
EA007540B1 (ru) 2006-10-27
OA12909A (en) 2006-10-13
PL375988A1 (en) 2005-12-12
PA8579701A1 (es) 2005-05-24
TWI250162B (en) 2006-03-01
BR0313683A (pt) 2005-06-21
IL166719A0 (en) 2006-01-15
AR041028A1 (es) 2005-04-27

Similar Documents

Publication Publication Date Title
HN2003000227A (es) Inhibidores de quinasas
BRPI0413363A (pt) formas de dosagem fornecendo liberação controlada de inibidores de proteìna de transferência de ésteres de colesterila e liberação imediata de inibidores de hmg-coa redutase
GT200400092A (es) Preparacion y uso de derivados de alquilarilo para el tratamiento de la obesidad
ECSP045429A (es) Combinacion de compuestos organicos
GT200100152A (es) Nueva composicion farmaceutica para el tratamiento de la obesidad.
PA8572701A1 (es) Inhibidores de metaloproteinasa de heteroariloxi-aril-espiro-pirimidina-2,4,6-triona n-sustituida
ECSP055747A (es) Antagonistas de cgrp elegidos, procedimiento para su preparación, así como su empleo como medicamentos
RS52945B (en) PHARMACEUTICAL FORMULATIONS AND THEIR APPLICATION IN THE TREATMENT OF WOMEN SEXUAL DYSFUNCTION
BRPI0512938A (pt) derivados da quinazolinediona como inibidores parp
NI200700107A (es) (bifenil) ácidos carboxílicos y sus derivados
GT200600444A (es) Compuestos anti-hipercolesterolemicos
AR062794A1 (es) Composiciones y metodos para el tratamiento de enfermedades virales
GT200500027A (es) Derivados de tetrahidroisoquinolinilo de quinazolina e isoquinolina
ECSP056173A (es) Composicion que comprende un inhibidor de pde4 y un inhibidor de pde5
PA8572201A1 (es) Inhibidores de metaloproteinasa de triaril-oxi-aril-espiro-pirimidina-2,4,6-triona
GT200300033A (es) Derivados de nicotinamida utiles como inhibidores de pde4
EA200401183A1 (ru) Применение ингибиторов il-18 в качестве диагностического маркера
CR9495A (es) Composicion en emulsion estable
MA28176A1 (fr) Inhibiteurs de la forme mutante du kit
BRPI0514544A (pt) ácidos de oxazol-naftila como moduladores de inibidor tipo-1 de ativador de plasminogênio (pai-1)
SV2009003152A (es) Derivados novedosos de aminopiridina que tiene accion inhibidora selectiva sobre aurora a
GT200300179A (es) Profarmaco inhibidor de beta-lactamasa
UY29774A1 (es) Inhibidor de atm
GT200100145A (es) Derivados de pirrolidina.
BRPI0603783A (pt) composições e métodos para redução do ph vaginal